- Home
- ESGL vs MDXH Comparison
ESGL vs MDXH Comparison
Compare ESGL & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- MDXH
- Stock Information
- Founded
- ESGL 1999
- MDXH 2003
- Country
- ESGL Singapore
- MDXH Belgium
- Employees
- ESGL 72
- MDXH N/A
- Industry
- ESGL
- MDXH
- Sector
- ESGL
- MDXH
- Exchange
- ESGL Nasdaq
- MDXH Nasdaq
- Market Cap
- ESGL 99.1M
- MDXH 84.6M
- IPO Year
- ESGL N/A
- MDXH 2021
- Fundamental
- Price
- ESGL $2.30
- MDXH $2.04
- Analyst Decision
- ESGL
- MDXH Buy
- Analyst Count
- ESGL 0
- MDXH 1
- Target Price
- ESGL N/A
- MDXH $6.00
- AVG Volume (30 Days)
- ESGL 35.3K
- MDXH 73.2K
- Earning Date
- ESGL 06-03-2025
- MDXH 05-14-2025
- Dividend Yield
- ESGL N/A
- MDXH N/A
- EPS Growth
- ESGL N/A
- MDXH N/A
- EPS
- ESGL N/A
- MDXH N/A
- Revenue
- ESGL $6,099,784.00
- MDXH $94,507,000.00
- Revenue This Year
- ESGL N/A
- MDXH $23.43
- Revenue Next Year
- ESGL N/A
- MDXH $17.06
- P/E Ratio
- ESGL N/A
- MDXH N/A
- Revenue Growth
- ESGL N/A
- MDXH 25.46
- 52 Week Low
- ESGL $0.86
- MDXH $1.35
- 52 Week High
- ESGL $3.00
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- ESGL 61.13
- MDXH 64.31
- Support Level
- ESGL $1.71
- MDXH $1.67
- Resistance Level
- ESGL $2.43
- MDXH $2.29
- Average True Range (ATR)
- ESGL 0.19
- MDXH 0.14
- MACD
- ESGL 0.01
- MDXH 0.02
- Stochastic Oscillator
- ESGL 81.52
- MDXH 58.95
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.